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ABSTRACT 23 
Background: Trypanosoma cruzi, the causative agent of Chagas’, disease is unable to 24 
synthesise its own purines and relies on salvage from the host. In other protozoa, purine uptake 25 
has been shown to be mediated by Equilibrative Nucleoside Transporters (ENTs).  26 
 27 
Methods: To investigate the functionality of T. cruzi-encoded ENT transporters, its four 28 
putative ENT genes (TcrNB1, TcrNB2, TcrNT1 and TcrNT2) were cloned and expressed in 29 
genetically adapted Trypanosoma brucei procyclic cells from which the nucleobase transporter 30 
locus was deleted.  31 
 32 
Results: TcrNB1 displayed very high affinity for hypoxanthine (Km 93.8 ± 4.7 nM for) and 33 
guanine, and moderate affinity for adenine. TcrNT1 was found to be a high-affinity 34 
guanosine/inosine transporter (inosine Km is 1.0 ± 0.03 µM; guanosine Ki is 0.92 ± 0.2 µM). 35 
TcrNT2 encoded a high-affinity thymidine transporter (Km = 223.5 ± 7.1 nM) with a clear 36 
preference for 2’-deoxypyrimidines. TcrNB2, whose activity could not be determined in our 37 
system, could be a low-affinity purine nucleobase transporter, given its sequence and predicted 38 
structural similarities to Leishmania major NT4. All 4 transporter genes were highly expressed 39 
in the amastigote forms, with much lower expression in the non-dividing stages.  40 
 41 
Conclusions: The data appear to show that, surprisingly, T. cruzi has a preference for 42 
oxopurines over aminopurines and efficiently transports 2’-deoxypyrimidines. The T. cruzi 43 
ENTs display exceptionally high substrate affinity as an adaptation to their intracellular 44 
localisation. 45 
 46 
General Significance: This study reports the first cloning of T. cruzi purine and pyrimidine 47 
transporters, including the first gene encoding a pyrimidine-selective protozoan transporter.  48 
 49 
Keywords: Trypanosoma cruzi; Equilibrative Nucleoside Transporter; Thymidine transporter; 50 
Pyrimidine-specific uptake; Trypanosoma brucei; heterologous expression. 51 
1. INTRODUCTION 52 
 The group Trypanosomatida comprises 22 recognized genera of protist parasites of 53 
plants and animals, vertebrates and invertebrates, among which the genera Leishmania and 54 
Trypanosoma stand out as causative agents of important human diseases, such as leishmaniasis 55 
(Leishmania spp.), sleeping sickness (Trypanosoma brucei) and Chagas’ disease 56 
(Trypanosoma cruzi) [1]. In contrast to the extracellular lifecycle observed for most of the 57 
known animal trypanosomes and, probably, by the putative ancestral trypanosomatid, T. cruzi 58 
evolved an intracellular lifestyle [2–4]. Therefore, the study of its biological needs might depict 59 
adaptations towards the survival in its intracellular milieu. 60 
 T. cruzi is transmitted to mammalian hosts through the bite of the bloodsucking 61 
triatomine bugs, and is endemic to the American continent, infecting humans as well as 62 
domestic and wild animals, from the north of Argentina to the southern USA [5], with an 63 
estimated 8 million people infected worldwide and more than 70 million living under risk of 64 
infection [5,6]. The three most relevant stages of its life cycle are: epimastigotes, in the 65 
triatomine’s intestine; trypomastigotes, in the distal part of the intestines of the vectors 66 
(metacyclic trypomastigotes) and in the mammalian bloodstream; and the intracellular 67 
amastigote forms [6,7]. 68 
 The first record of a human infection by T. cruzi was found in an Andean mummy dated 69 
from approximately 9000 years ago [8], showing that T. cruzi has been circulating within 70 
human populations for a long time, and certainly for much longer among sylvatic animals. In 71 
fact, the divergence of trypanosomatids from other eukaryotes (200 – 500 million years ago) 72 
[9–11], corresponds to the period in which arthropods and mammals first emerged [12]. The 73 
evolution of trypanosomatids towards parasitism is supported by the recent finding that the 74 
basal trypanosomatid Paratrypanosoma confusum, from which many characteristics were 75 
inherited by other genera of parasites in this family [3], is a parasite of mosquitoes [2]. Among 76 
the many adaptations to parasitism we note the incapacity of all protozoan parasite so far 77 
investigated to synthesise purines de novo, causing an absolute reliance on their uptake from 78 
the host [13,14]. 79 
 To deal with the scarcity of free purine nucleobases and nucleosides available in the 80 
intra-host environment, these parasites have developed several purine uptake mechanisms. 81 
Although it has been proposed that trypanosomatids may encode nucleoside transporters of an 82 
as yet unidentified gene family [15–17], to date only members of the Equilibrative Nucleoside 83 
Transporters (ENTs) family have been identified in their genomes and, therefore, are assumed 84 
to be the main carriers responsible for purine and/or pyrimidine uptake mechanisms in these 85 
cells [13]. Interestingly, protozoan ENT transporters seem to be concentrative and mono-86 
directional rather than equilibrative, and proton-symporters [18–22]. 87 
 Although ENT genes from T. brucei and different species of Leishmania have been 88 
cloned and characterised in depth, not much is known about purine and pyrimidine transport 89 
mechanisms in other trypanosomatids. For instance, there is only one report on purine transport 90 
in Trypanosoma congolense, a cattle parasite with high economic impact in Africa [23], and 91 
the last report on purine transport by T. cruzi dates from 25 years ago  [24,25]. These early 92 
studies describe the relationship between nucleoside transport and resistance to tubercidin (7-93 
deazaadenosine), and postulated the existence of at least three transport mechanisms in T. cruzi: 94 
one for pyrimidines and tubercidin, one for thymidine with no affinity for tubercidin, and one 95 
for adenosine and inosine [24,25]. However, the depletion of purines such as inosine, 96 
guanosine, hypoxanthine and adenine in T. cruzi-infected cardiomyocytes [26] indicates the 97 
existence of a more complex and unexplored array of nucleoside and nucleobase transporters 98 
in this parasite. Herein, we cloned and characterized each T. cruzi ENT gene separately in an 99 
adapted T. brucei cell line, in order to determine their substrate specificity and affinity. We 100 
show that T. cruzi encodes for high-affinity nucleobase and nucleoside transporters with 101 
exceptionally high substrate affinity, which must be an important adaptation to an intracellular 102 
environment that contains very low concentrations of free nucleosides and nucleobases. 103 
 104 
2. MATERIALS AND METHODS 105 
2.1. Cells and culturing conditions 106 
2.1.1. Trypanosoma brucei 107 
 Given the extent of studies on ENT genes from T. brucei, and the organism’s 108 
amenability to genetic manipulation, we used it as a surrogate system for the characterisation 109 
of ENTs from T. cruzi. Procyclic forms (PCF) of T. brucei strain Lister 427 (427WT) were 110 
maintained at 27 °C in non-vented plastic flasks with SDM-79 medium (Gibco) supplemented 111 
with 10% Foetal Bovine Serum (FBS, Gibco) and 7.5 µg/mL haemin. From 427WT the three 112 
genes making up the NT8 cluster on chromosome 11 [27,28] were deleted by homologous 113 
recombination, using the strategy previously reported by us for bloodstream forms [17], 114 
creating a new, procyclic TbNBT-KO cell line. The knockout was confirmed both by PCR and 115 
by phenotypical characterisation. 116 
 117 
2.1.2. Trypanosoma cruzi 118 
 For qRT-PCR, total RNA was extracted from epimastigotes, metacyclic 119 
trypomastigotes, cell-derived trypomastigotes and amastigotes of T. cruzi (strain CL, clone 14) 120 
[29]. Epimastigotes and metacyclic trypomastigotes were obtained exactly as previously 121 
described. Briefly, exponentially growing T. cruzi epimastigotes were maintained in LIT 122 
medium supplemented with 10% fetal calf serum (FCS) by sub-culturing every 48 h and 123 
metacyclic trypomastigotes were obtained by in vitro differentiation of stationary growth phase 124 
epimastigotes as follows. Epimastigotes (5 × 108) were washed in PBS, resuspended in TAU 125 
medium (190 mM NaCl, 17 mM KCl2, 2 mM MgCl2, 2 mM CaCl2, 8 mM phosphate buffer, 126 
pH 6.0) [30] and incubated for 2 h at 28 ºC. Then, the cells were supplemented with 10 mM 127 
proline and maintained for in vitro differentiation over 6 days, with daily counting in a 128 
Neubauer chamber. The cells (of which 30% metacyclic trypomastigotes) were washed in PBS, 129 
resuspended in cold 2% glucose in PBS adjusted to pH 8.0, and submitted to purification using 130 
an anionic exchange chromatography [31]. A DEAE-cellulose matrix (Sigma-Aldrich) was 131 
packed in a column and equilibrated with 2% glucose in PBS, pH 8.0. Parasites were applied 132 
onto the column, and fractions of 2 ml were collected. The presence of live cells containing 133 
trypomastigotes was microscopically monitored. The fractions containing more than 95% of 134 
metacyclic forms were pooled, washed and resuspended in PBS.  135 
 Amastigotes and trypomastigotes were obtained from the infection of a Chinese 136 
Hamster Ovary cell line (CHO-K1) as previously described [32], with minor modifications. 137 
Briefly, CHO-K1 cells were grown in RPMI medium supplemented with 10% FCS and 0.15% 138 
(w/v) NaCO3, at 37 °C in a 5% CO2 atmosphere. Cells were infected with trypomastigotes 139 
obtained from previous infections at a proportion of 50 trypomastigotes/cell. Amastigotes were 140 
collected at day 2 post-infection from the host-cell cytoplasm by treating the cells with a cold 141 
solution of 0.05% (w/v) SDS in PBS for 2 min, followed by a quick washing with cold 142 
PBS/10% FCS. Cells were disrupted with a rubber policeman, and amastigotes released into 143 
the supernatants were recovered and washed in cold PBS. Trypomastigotes were harvested 144 
from the extracellular medium at days 6 and 7 post-infection. The viability of the parasites, as 145 
well as the purity of each life-cycle stage preparation, was evaluated by direct microscopic 146 
observation. 147 
 148 
2.2. Plasmid construction and transfection 149 
 Sequences encoding for ENTs in T. cruzi were found by their annotation on TritrypDB. 150 
Out of the eight sequences annotated as nucleoside or nucleobase transporters, two 151 
(TcCLB.506203.10 and TcCLB.508645.70) were very short, with transcripts of 543 and 390 152 
base pairs in length, respectively, and are unlikely to encode for functional transporters, and, 153 
thus, were not included in our analysis. Among the six remaining coding sequences, four open 154 
reading frames (ORFs) represented two genes as Esmeraldo- and Non-Esmeraldo-like 155 
sequences (TcCLB.511051.30 and TcCLB.509683.110 encode for TcrNB1 (99% identity) and 156 
TcCLB.506773.50 and TcCLB.508799.150 encode for TcrNB2 (98% identity); Table 1) and 157 
are very likely to present the same substrate affinity. Primers specific for each gene were 158 
designed (Table S1) and the ORFs were amplified from genomic DNA of T. cruzi Y strain with 159 
the high-fidelity proof-reading Phusion DNA polymerase and cloned into the pHD1336 vector 160 
[23] for heterologous expression in T. brucei procyclic TbNBT-KO cells. 161 
 162 
Table 1. Annotation of Equilibrative Nucleoside Transporters in the T. cruzi genome 163 
Gene code Chromosome Profile‡ Transcript 
Given 
name* 
Genbank 
(Y strain) 
TcCLB.511051.30 
14 
Esm 
1374 bp TcrNB1§† 
MH453384; 
MH453385 TcCLB.509683.110 Non-Esm 
TcCLB.506773.50 
27 
Esm 
1347 bp TcrNB2§ MH453386 
TcCLB.508799.150 Non-Esm 
TcCLB.508645.40 26 Non-Esm 1407 bp TcrNT1† 
MH453387; 
MH453388 
TcCLB.506445.110 7 Non-Esm 1323 bp TcrNT2 MH453389 
TcCLB.506203.10 26 Esm 543 bp --  
TcCLB.508645.70 26 Non-Esm 390 bp --  
*Also refer to Figure 1. 164 
‡Esm: Esmeraldo-like; Non-Esm: Non-Esmeraldo-like, as annotated in the T. cruzi genome reference CL Brener 165 
strain. 166 
§Only Esmeraldo-like sequences were identified in T. cruzi Y strain. 167 
†Heterozygous profile identified in T. cruzi Y strain. The sequence closer to that found in the genome reference 168 
was used for heterologous expression in T. brucei: TcrNB1_1 (MH453384) and TcrNT1_2 (MH453388). 169 
 170 
 All the constructs were linearized with NotI (or SacII for pHD1336 containing 171 
TcrNT2), precipitated with 100% ethanol, dried at 40 °C, resuspended in water and transfected 172 
by electroporation in an Amaxa Nucleofector (Lonza), using program X-014. A control group 173 
was electroporated in parallel without added DNA. After 12-16 h, 20 µg/mL of blasticidin was 174 
added to the culture to positively select the successfully transfected parasites. After further 175 
three days, 100 µL of culture was transferred to fresh medium with the same antibiotic. When 176 
no living cells were observed in the no-DNA control group, parasites transfected with the T. 177 
cruzi gene constructs were plated out at 0.3 parasite/well in 96-well plates in the continued 178 
presence of blasticidin. Two clonal populations were randomly selected for each studied gene 179 
and used in transport assays in parallel with TbNBT-KO cells transfected with the ‘empty’ 180 
vector pHD1336 (TbNBT-KO+EV). After selection, cells were always grown in the presence 181 
of 10 µg/mL of blasticidin. 182 
 183 
2.3. Transport assays 184 
 Uptake of tritiated purines or pyrimidines was assayed exactly as described previously 185 
[17]. Briefly, 1×107 cells were incubated with radiolabelled substrate for a predetermined time 186 
in uptake assay buffer (AB, pH 7.3 [23]) and the reaction was stopped by the addition of ice-187 
cold unlabelled substrate (2 mM in AB) followed by centrifugation of cells through an oil layer, 188 
flash-freezing in liquid Nitrogen, lysis with 2% SDS for at least 1 h under agitation, and 189 
incubation with scintillation fluid (Scintlogic U, Lablogic) overnight. Samples were read in a 190 
Hidex 300SL scintillation counter. All assays were carried out in triplicate. 191 
 When the substrate specificity of a transporter was not clear by its position in the 192 
phylogenetic tree, its main substrate was identified by incubation of the correspondent 193 
transfectant clones with 50 nM of each of a series of radiolabelled purine and pyrimidine 194 
nucleobases and nucleosides for one minute in parallel with TbNBT-KO+EV cells as 195 
background control. 196 
  Km and Ki values for each transporter were determined as described [33] by incubation 197 
of cells with a low, non-saturating concentration of an appropriate radiolabelled substrate, and 198 
increasing concentrations of unlabelled substrate for a set duration that was well within the 199 
linear range of transport. The resulting transport data was plotted to obtain Km and Vmax using 200 
the Michaelis-Menten equation (V0 = Vmax×[S]/(Km+[S]) in which [S] is the substrate 201 
concentration). Inhibition constants Ki were obtained in experiments with a fixed radiolabel 202 
concentration [S] several-fold below Km and a variable concentration of an inhibitor. The 203 
inhibitor concentration was plotted against the rate of transport using a sigmoid curve with 204 
variable slope (Prism 5.0, GraphPad); the IC50 value was entered into the Cheng-Prusoff 205 
equation to obtain the Ki: Ki = IC50/(1+([S]/Km)) [34]. From this, the Gibbs free energy (ΔG0) 206 
of the inhibitor-transporter interaction was calculated using the equation ΔG0 = −RTln(Ki), 207 
where R is the gas constant and T is the reaction absolute temperature. It should be noted that 208 
these equations apply to competitive inhibitors, which is likely to be the case given that the 209 
inhibition curves presented Hill slopes consistently near −1, indicating the inhibition of a single 210 
transport mechanism (the T. cruzi ENT gene expressed), and that the inhibitors used were all 211 
natural nucleosides and nucleobases. 212 
 213 
2.4. qRT-PCR 214 
 Total RNA of 1 × 108 cells of three independent preparation of each T. cruzi stage and 215 
CHO-K1 cells was extracted using TRIzol reagent (Invitrogen) according to the manufacturer’s 216 
instructions.  RNA samples were treated for 1 h with DNAse I Amplification Grade kit 217 
(Invitrogen) as recommended by the manufacturer, to eliminate any contaminating DNA. The 218 
RNA samples were recovered from the supernatants, spectrophotometrically quantified, and 219 
quality checked for the presence of remaining DNA by performing a PCR assay using the same 220 
primers designed for qRT-PCR (Table S1). The RNA samples (5 µg) were submitted to reverse 221 
transcription using a random primer set and SuperScript III Reverse Transcriptase (Invitrogen) 222 
according to the manufacturer’s protocol. Primers for amplification of the ENTs (Table S1) 223 
were designed based on the sequences encoding for T. cruzi ENTs described above. The 224 
primers corresponding to the housekeeping control (TcrGAPDH, GenBank accession number 225 
AI007393) have been previously reported [32]. The qRT-PCR was performed independently 226 
on three separate occasions (biological replicates), each time in triplicate (technical replicates), 227 
using the Fast SYBR Green Master Mix (Invitrogen) quantification system following the 228 
manufacturer’s instructions, in a Mastercycler ep RealPlex (Eppendorf) using the following 229 
conditions: 95 ºC for 15 s, 40 cycles of 95 ºC (15 s), 59 ºC (15 s), and 68 ºC (15 s), followed 230 
by a denaturation curve. In order to compare the raw level of transcription of each gene for 231 
each biological form, their transcriptional level was measured as fold-change of the 232 
transcriptional level obtained for GAPDH in each biological replicate (2(Ct(GAPDH)-Ct(transporter)). 233 
 234 
2.5. Drug sensitivity assays 235 
 Fifty percent effective concentrations (EC50) were determined essentially as described 236 
for bloodstream form T. brucei [35], using the viability indicator dye resazurin [36]. Briefly, 237 
4×104 procyclic cells were incubated in 200 µL of SDM-79 with various concentrations of two-238 
fold serially diluted pentamidine or 5-Fluoro-2’-deoxyuridine for 72 h at 27 ºC in a 96-well 239 
plate prior to the addition of 20 µL of 5 mM resazurin sodium salt (Sigma-Aldrich) and further 240 
incubation for 24 h. The highest concentration of test drug used was 100 µM, followed by 23 241 
doubling dilutions over 2 rows of the plate, with the last well used as no-drug control. 242 
Fluorescence for each well was measured in a FLUOstar Optima (BMC Labtech) with 243 
excitation at 544 nm and emission at 620 nm, and the EC50 was calculated by sigmoidal non-244 
linear regression with variable slope, using GraphPad Prism 5. 245 
 246 
3. RESULTS 247 
3.1. Genomic analysis of ENT genes in trypanosomatids 248 
 In order to better understand the phylogenetic relationship between ENT transporters 249 
from T. cruzi and from other trypanosomatids, a phylogenetic analysis was made based on the 250 
sequences available on the TriTrypDB genomic database for T. cruzi, T. brucei, T. congolense 251 
and Leishmania spp (http://tritrypdb.org/tritrypdb/). The phylogenetic tree shows a clear 252 
division between nucleobase (T. brucei NT8 nucleobase transporters, Leishmania NT3 and 253 
NT4 clusters) and nucleoside transporters (T. brucei P1 and P2 clusters and Leishmania NT2 254 
cluster) (Figure 1). The NT1 transporters in Leishmania form a separated branch, probably 255 
because of their ability to transport both purine and pyrimidines nucleosides [37–39]. Ali et al. 256 
(2013) showed that P1 transporters can also transport thymidine, but it is not the main substrate 257 
of this group of proteins [40]. The genes encoding for pyrimidine-only transporters in T. brucei 258 
and Leishmania spp (e.g. uracil transporters TbU1, LmU1, TbU3) have not been identified yet, 259 
and thus their inclusion in the purine transporter tree is not possible [15,16,21,41,42]. 260 
 The proximity between TcrNB1 and the T. brucei nucleobase transporter clade 261 
indicates that it was very probably a high-affinity purine nucleobase transporter. TcrNB2 seems 262 
to be closer to the Leishmania NT4 nucleobase transporters cluster; LmjNT4 is a low-affinity 263 
purine nucleobase transporter that works better in acidic conditions, being important for the 264 
survival of Leishmania amastigotes in the macrophage [43]. Similarly, TcrNT1 could be 265 
hypothesized to be a purine nucleoside transporter, with possibly some capacity for pyrimidine 266 
nucleosides and/or purine nucleobases as well, due to its proximity to both P1 (high affinity 267 
for purine nucleosides; low affinity for pyrimidine nucleosides) and P2 (adenosine/adenine) 268 
clusters and to Leishmania NT2 (inosine/guanosine). TcrNT2 was grouped more closely to 269 
Leishmania NT1 transporters (adenosine/uridine), which might indicate it to be a 270 
purine/pyrimidine nucleoside transporter. This grouping is further supported by the similarity 271 
of the predicted structures of the T. cruzi ENT transporters with their closest homologues, as 272 
modelled by the Phyre2 software package (Figure S1). In order to confirm these predictions, 273 
all four ENT genes from T. cruzi were cloned and expressed in a genetically adapted T. brucei 274 
procyclic cell line (TbNBT-KO), from which the TbNT8.1 - NT8.3 locus on chromosome 11 275 
was deleted by homologous recombination. 276 
 277 
3.2. Systematic biochemical characterization of T. cruzi ENT genes: T. brucei as a surrogate 278 
system 279 
 In bloodstream forms of T. brucei, the deletion of the three NT8 genes arranged in 280 
tandem on chromosome 11, encoding for high affinity purine nucleobase transporters [27,28], 281 
had little effect on the overall transport rate of hypoxanthine or adenine in vitro [17]. However, 282 
hypoxanthine transport in the procyclic forms has been assigned to be mainly (~85%) 283 
performed by the H4 activity, which is encoded by an NT8 transporter [27]. We therefore 284 
knocked out the NT8 cluster in T. brucei PCF as previously described for bloodstream forms 285 
[17]. These procyclic TbNBT-KO cells displayed an 86% reduction in the rate of 0.1 µM [3H]-286 
Hypoxanthine uptake in comparison to s427 wildtype procyclic cells (Figure 2), from 0.036 ± 287 
0.007 pmol.(107 cells)-1.s-1 to 0.005 ± 0.0005 pmol.(107 cells)-1.s-1 (n = 3; P<0.03 by Paired 288 
Student’s T-test). The highly diminished rate of hypoxanthine transport in these cells permitted 289 
their use for heterologous expression of potential T. cruzi purine nucleobase transporters. 290 
 291 
3.2.1. TcrNB1 is a high-affinity hypoxanthine transporter 292 
 The expression of TcrNB1 in TbNBT-KO cells allowed us to test the prediction from 293 
the phylogenetic analysis of it being a purine nucleobase transporter. Indeed, expression of 294 
TcrNB1 in these cells increased their uptake rate for 50 nM [3H]-Hypoxanthine by 170-fold 295 
relative to empty vector controls performed in parallel,  with a linear phase of 6 s (0.36 ± 0.07 296 
versus 0.0021 ± 0.0007 pmol.(107 cells)-1.s-1; n=2, r2>0.99) (Figure 3). The addition of 1 mM 297 
of unlabelled hypoxanthine completely abolished the uptake of [3H]-Hypoxanthine indicating 298 
a complete saturation of the transporter under those conditions (Figure 3). In order to further 299 
analyse the transport of hypoxanthine (and not its metabolism), inhibition experiments were 300 
performed using 2 s incubations, very much within the linear phase of transport. The rate of 50 301 
nM [3H]-Hypoxanthine uptake measured for TbNBT-KO+EV was always below 0.7% of that 302 
measured for TbNBT-KO+TcrNB1, and inhibition profiles were therefore considered to 303 
represent inhibition of TcrNB1 only, which was consistent with our constant obtainment of 304 
sigmoid curves with Hill slopes near -1. 305 
 Given the high level of hypoxanthine transport by TbNBT-KO+TcrNB1 at 50 nM of 306 
radiolabel, it was likely to represent a high-affinity purine nucleobase transporter. Indeed, we 307 
found TcrNB1 to have a Km of 93.8 ± 4.7 nM for hypoxanthine (n=4; Figure 4A). The affinity 308 
for guanine was almost identical to this as it inhibited the transport of 50 nM [3H]-309 
Hypoxanthine with a Ki of 121.9 ± 22.4 nM (Figure 4B; Table 2). However, TcrNB1 displayed 310 
a much lower affinity for adenine, which inhibited the transport of hypoxanthine with a Ki of 311 
3.73 ± 0.5 µM, corresponding to the loss 10.2 KJ/mol in the Gibbs free energy of interaction 312 
relative to hypoxanthine (Table 2). This amount of interaction energy is likely to correspond to 313 
one hydrogen bond, indicating that TcrNB1 probably forms a hydrogen bond with the keto 314 
group on C6 or the protonated N1 residue, but not with the amino group of adenine or the 315 
protonated N1. While this indicates a strong selectivity for oxopurines over aminopurines, 316 
xanthine displayed even lower affinity than adenine for the transporter (Ki of 18.36 ± 1.83 µM, 317 
δ(ΔG0) = 14.1 KJ/mol relative to hypoxanthine) (Figure 4B), indicating that either the 318 
unprotonated N3 acts as an H-bond acceptor and/or the keto group causes substantial 319 
repulsion/steric hindrance between substrate and transporter (Table 2). Purine nucleosides were 320 
found to display much lower affinity than their respective nucleobases, with Ki values of 314.8 321 
± 26.5 µM and 17.1 ± 5.1 µM for inosine and guanosine, respectively, and no observable 322 
inhibition by adenosine (Table 2).  323 
 324 
Table 2. Ki for purines on the transport of [
3H]-Hypoxanthine by TcrNB1 325 
IC50 values obtained were converted to Ki based on the Km of TcrNB1. 326 
Purine Km or Ki (μM) ΔG0 δ(ΔG0) n 
Hypoxanthine 0.093 ± 0.004 -40.1 -- 4 
Adenine 3.73 ± 0.5 -29.9 10.2 3 
Guanine 0.122 ± 0.022 -38.4 1.7 3 
Xanthine 18.36 ± 1.83 -26 14.1 3 
Adenosine N.E. (1 mM) -- -- 3 
Guanosine 17.1 ± 5.1 -26.1 14 5 
Inosine 314.78 ± 26.5 -18.9 21.2 3 
Value highlighted in bold represents the Km for hypoxanthine. N.E. – No effect. 327 
   328 
Pyrimidines had very little or no effect on the transport of 50 nM of [3H]-Hypoxanthine 329 
by TcrNB1 (Figure 4C). When tested at a concentration of 1 mM, cytidine was the only 330 
pyrimidine able to inhibit the transport via TcrNB1 by more than 50% (59.4 ± 2.6%, n=3, 331 
P=0.006). In addition, 1 mM of cytidine or thymidine displayed minor effects on hypoxanthine 332 
uptake (P<0.05 by Unpaired Student’s T-test) but no effect was observed with 1 mM of any of 333 
the pyrimidine nucleobases. We thus conclude that TcrNB1 is a high affinity purine nucleobase 334 
transporter, rather than a nucleobase/nucleoside carrier, with specificity for hypoxanthine and 335 
guanine only. 336 
Moreover, it should be highlighted that the Km of TcrNB1 for hypoxanthine is orders of 337 
magnitude different from that reported for its intracellular metabolizing enzymes in T. brucei 338 
[44], which confirms once more that the herein measured kinetic and affinity parameters are 339 
from the transporter and not due to the intracellular metabolism of the radiolabelled. The same 340 
logic applies to the following characterised transporters [45–47]. 341 
 342 
3.2.2. TcrNT1 is a high-affinity inosine/guanosine transporter 343 
 The proximity of TcrNT1 to the P1 and P2 gene clusters from T. brucei and TcoAT1 344 
from T. congolense (Figure 1) indicated that it is likely to be a nucleoside transporter. 345 
Notwithstanding, we did not know whether it was going to have affinity for oxopurines (inosine 346 
and guanosine), as T. brucei P1, or for adenosine, as both P1 and P2, or for the three of them 347 
[48]. Therefore, we decided to screen several substrates at 50 nM by measuring their uptake 348 
during 1 min, in TbNBT-KO+EV and TbNBT-KO+TcrNT1 cells. During preliminary testing 349 
of substrates with both strains in parallel, we found that the transport of inosine and guanosine 350 
was increased in TbNBT-KO+TcrNT1 by approximately 30%. Given its higher specific 351 
activity, we decided to use [3H]-Inosine as our probe for the further assays.  352 
 The use of [3H]-Inosine, however, still entails the problem of high background 353 
generated by its uptake via P1 [49]; the P2 aminopurine transporter is not expressed in procyclic 354 
T. brucei [20]. We therefore screened several known substrates of P1 as specific inhibitors of 355 
[3H]-Inosine uptake mediated by P1 but not TcrNT1. As we observed that that adenosine is not 356 
a very good substrate for TcrNT1, we verified that analogues of this nucleoside showed high 357 
potential as good inhibitors of P1 with low affinity for TcrNT1. Among them, 2’-deoxy-2’-358 
Fluoro-adenosine (2’F-Ado) showed the best results: incubation of TbNBT-KO+TcrNT1 with 359 
50 nM [3H]-Inosine in presence of increasing concentrations of 2’F-Ado yielded quite different 360 
IC50 values for P1 and TcrNT1 (200.5 ± 14.7 nM and 40.5 ± 8.6 μM, respectively), when plotted 361 
with a two-site competition non-linear regression (Figure 5A). The IC50 for 2’-F-Adenosine on 362 
P1 was further confirmed by inhibition of inosine transport via P1 only in TbNBT-KO+EV 363 
(177.9 ± 20.2 nM) and followed monophasic inhibition kinetics with a sigmoid curve with a 364 
Hill slope of -1. We verified that the presence of 3.3 μM of 2’F-Ado in the reaction almost 365 
completely saturated P1, reducing the transport of [3H]-Inosine by TbNBT-KO+EV from 0.048 366 
± 0.003 to 0.002 ± 0.0004 pmol.(107 cells)-1.s-1, without affecting TcrNT1-mediated [3H]-367 
Inosine transport (Figure 5A). By thus inhibiting P1 with 3.3 μM of 2’F-Ado we observed a 368 
reduction of 48 ± 4% in the uptake of [3H]-Inosine by TbNBT-KO+TcrNT1 cells (from 0.072 369 
± 0.003 to 0.041 ± 0.002 pmol.(107 cells)-1.s-1), which remained linear for at least 12 s (r2 = 370 
0.99; Figure 5B). The addition of 1 mM unlabelled inosine completely saturated the transport 371 
of [3H]-Inosine, showing the transport mechanism to be saturable (Figure 5B).  372 
We next investigated the substrate specificity and affinity of TcrNT1 for a range of 373 
purines and pyrimidines, using competition assays with 50 nM [3H]-Inosine transport over 8 s, 374 
in the presence of 3.3 μM of 2’F-Ado. Incubation with increasing concentrations of unlabelled 375 
inosine revealed a high-affinity profile with a Km of 1.0 ± 0.04 μM (Figure 6A). Almost the 376 
same affinity was observed for guanosine (Ki of 0.92 ± 0.14 μM), but affinity for other purines 377 
was much lower: the Ki values for adenosine, hypoxanthine and xanthine were 38.9 ± 5.8 μM, 378 
23.9 ± 5.5 μM and 410.3 ± 35.7 μM, respectively (Figure 6B; Table 3). The Hill slope very 379 
close to -1 in all assays, indicating that the transport of [3H]-Inosine was mediated by a single 380 
transporter, i.e. TcrNT1, following saturation of P1-mediated uptake by 2’F-Ado at 3.3 μM. 381 
 Compared to inosine, adenosine and hypoxanthine displayed a substantially lower 382 
affinity for TcrNT1, resulting in a δ(ΔG0) of 9.2 KJ/mol and 8 KJ/mol (Table 3), respectively, 383 
which are both likely to be due to the loss of one hydrogen bond. This indicates that (1) either 384 
the keto group on C6 or the protonated N1 of the purine ring is part of the interaction with the 385 
transporter, as its substitution by an amino group, and consequent deprotonation of N1, in 386 
adenosine causes a loss of binding energy corresponding to the loss of one hydrogen bond; and 387 
that (2) the ribose group is also part of this binding with one point of interaction, as its absence, 388 
in hypoxanthine, affects the binding energy. In the case of xanthine, besides the absence of a 389 
ribose group, the loss of binding affinity is further associated with the presence of a keto group 390 
attached to C2, which may interact unfavourably an amino acid residue in the transporter 391 
binding pocket, or possibly cause a different orientation within the binding pocket. Adenine at 392 
1 mM did not significantly affected the transport of [3H]-Inosine via TcrNT1 (Figure 6C; P>0.3 393 
by Unpaired Student’s T-test). 394 
 395 
Table 3. Ki for purines on the transport of [
3H]-Inosine by TcrNT1 396 
IC50 values obtained were converted to Ki based on the Km of TcrNT1. 397 
Purine Km or Ki (μM) ΔG0 δ(ΔG0) n 
Inosine 1.0 ± 0.04 -34.23 -- 3 
Adenosine 38.9 ± 5.8 -25.04 -9.2 3 
Guanosine 0.92 ± 0.14 -34.31 0.08 4 
Guanine N.E. (25 μM) -- -- 3 
Hypoxanthine 23.9 ± 5.5 -26.25 -8 3 
Xanthine 410.3 ± 35.7 -19.2 -15 3 
Value highlighted in bold represents the Km for inosine. N.E. – No effect. 398 
 399 
 Pyrimidine nucleobases and nucleosides showed also very low affinity for TcrNT1, 400 
given that the transport of 50 nM of [3H]-Inosine was not completely blocked by any of them 401 
at 1 mM, i.e. a concentration 20,000× higher than the radiolabelled permeant (Figure 6C). 402 
Among them, cytidine, cytosine, thymine and uracil did not present any measurable affinity for 403 
the TcrNT1, and only thymidine and uridine significantly inhibited inosine transport by 404 
TcrNT1 (P<0.05 by Unpaired Student’s T-test). We conclude that TcrNT1 is a nucleoside 405 
transporter selective for inosine and guanosine. 406 
 407 
3.2.3. TcrNT2 is a high-affinity thymidine transporter 408 
 The clustering of TcrNT2 (TcCLB.506445.110) closest to the Leishmania NT1-type 409 
transporters, forming a separated group at the base of the phylogenetic tree (Figure 1), indicated 410 
it could be a purine/pyrimidine transporter. We thus screened a series of purine and pyrimidine 411 
radiolabelled nucleosides at 50 nM and observed that the transport of thymidine and uridine 412 
was increased by approximately 7,000-fold and 1.7-fold, respectively, in TbNBT-KO+TcrNT2 413 
compared to TbNBT-KO+EV in this single experiment (results not shown). Given that T. 414 
brucei does not have any dedicated thymidine transporter [40,41], we utilised this radiolabelled 415 
as a probe for the further transport experiments to characterise TcrNT2. 416 
 When TbNBT-KO+TcrNT2 cells were incubated with 25 nM of [3H]-thymidine, we 417 
observed a rate of transport of 0.007 ± 0.001 pmol.(107 cells)-1.s-1 that was linear for at least 1 418 
min (n=2; r2=0.99; Figure 7). The rate of uptake in TbNBT-KO+EV cells was not significantly 419 
different from zero, as well as identical to the groups incubated with 1 mM of unlabelled 420 
thymidine, showing that the uptake via TcrNT2 is saturable and confirming that TcrNT2 is the 421 
only high affinity thymidine transporter in these cells. Further experiments using TbNBT-422 
KO+TcrNT2 cells were carried using 30-second incubations. 423 
 In order to measure the affinity the affinity of TcrNT2 for pyrimidines and purines, 424 
TbNBT-KO+TcrNT2 cells were incubated with 25 nM of [3H]-thymidine in the presence of 425 
increasing concentrations of inhibitors. Interestingly, TcrNT2 was found to be specific for 2’-426 
deoxypyrimidines, given that it showed high affinity only for thymidine and 2’-deoxyuridine 427 
(Table 4). We measured a Km of 223.5 ± 7.1 nM for thymidine (Figure 8A), disclosing a high-428 
affinity profile for this nucleoside; the Hillslope of the inhibition plot was consistently very 429 
close to -1 (Figure 8A, inset), further evidence that thymidine transport was performed by a 430 
single mechanism in TbNBT-KO+TcrNT2 cells. 431 
 The preference of TcrNT2 for 2’-deoxypyrimidines becomes very clear when the 432 
affinities for uridine and 2’-deoxyuridine are compared (Figure 8B): Ki values of 65.5 ± 6.0 433 
μM and 1.11 ± 0.1 μM, respectively, meaning that the removal of the 2’ hydroxyl group from 434 
the ribose increased the affinity for TcrNT2 by 59-fold. This translates into a difference of 10.1 435 
KJ/mol in Gibbs free energy (ΔG0 of -23.9 KJ/mol for uridine and -34.0 KJ/mol for 2’-436 
deoxyuridine; Table 4). Most likely, the 2’-hydroxyl group is sterically not tolerated in the 437 
TcrNT2 binding pocket, and its presence causes a shift in the substrate position, with an 438 
attendant loss of 10 kJ/mol in interaction energy. The somewhat higher affinity of thymidine 439 
over 2’-deoxyuridine could be the result of a hydrophobic interaction of -4.0 kJ/mol between 440 
the 5-methyl moiety and the binding site (Table 4), although there could also be a contribution 441 
from higher electron density in the pyrimidine ring, which would enhance any π- π stacking 442 
interactions. Conversely, TcrNT2 showed very low affinity for cytidine (Ki of 728 ± 70.5; Table 443 
4), and the δ(ΔG0) of 5.9 kJ/mol relative to uridine indicates a binding interaction with either 444 
the 4-oxo group or with protonated N3. At 1 mM pyrimidine nucleobases showed no effect on 445 
[3H]-thymidine transport by TcrNT2, except for thymine which inhibited by 38.2 ± 1.6% of 446 
inhibition at this concentration, which translates into a δ(ΔG0) >20 KJ/mol relative to thymidine 447 
and the strong likelihood that the 2-deoxyribose contributes 2 hydrogen bonds to the binding 448 
of thymidine, probably at 3’ and 5’, as do the T. brucei P1 transporter [48,50] and the 449 
Toxoplasma gondii AT2 [51]. 450 
 Purines had almost no effect on TcrNT2-mediated transport, as 1 mM of each purine 451 
nucleoside or nucleobase (or 250 μM of guanosine, the highest concentration tested) failed to 452 
affect the transport of [3H]-Thymidine, with the exception of adenosine, which inhibited the 453 
transporter by 34.7 ± 1.1% at 1 mM, and yielded a Ki of 1556 ± 60 μM (Table 4). We therefore 454 
conclude that T. cruzi NT2 is a high affinity thymidine transporter that would also transport 2’-455 
deoxyuridine if this were present in its environment.  456 
 As the study of Finley, Cooney and Dvorak (1988) showed that the decreased ability of 457 
laboratory-generated tubercidin-resistant clones of T. cruzi to transport radiolabelled tubercidin 458 
was associated with a decrease in the transport of thymidine and uridine, we evaluated whether 459 
tubercidin could also be a substrate for TcrNT2. Interestingly, TcrNT2 showed two-fold higher 460 
affinity for tubercidin than for adenosine (Ki of 695.7 ± 109.3 μM (n=2)) in competition to 25 461 
nM [3H]-Thymidine; Table 4), but is still a low-affinity substrate for this transporter. 462 
 463 
Table 4. Ki for purines and pyrimidines on the transport of [
3H]-Thymidine by TcrNT2 464 
IC50 values obtained were converted to Ki based on the Km of TcrNT2. 465 
Inhibitor Km or Ki (μM) ΔG0 δ(ΔG0) n 
Thymidine 0.223 ± 0.007 -37.95 -- 3 
Uridine 65.5 ± 6.0 -23.9 14.1 3 
2’-deoxyuridine 1.11 ± 0.1 -34.0 3.98 3 
Cytidine 728 ± 70.5 -17.9 20.0 3 
Thymine > 1 mM -- >20 3 
Uracil N.E. (1 mM) -- -- 3 
Cytosine N.E. (1 mM) -- -- 3 
Adenine N.E. (1 mM) -- -- 3 
Adenosine 1556 ± 60 -16.0 21.9 3 
Guanosine N.E. (250 μM) -- -- 3 
Hypoxanthine N.E. (1 mM) -- -- 3 
Inosine N.E. (1 mM) -- -- 3 
Xanthine N.E. (1 mM) -- -- 3 
Tubercidin 695.7 ± 109.3 -18.0 19.9 2 
Value highlighted in bold represents the Km for thymidine. N.E. – No effect. 466 
 467 
3.2.4. TcrNB2 is an ENT of unknown function 468 
 The position of TcrNB2 in the phylogenetic tree (Figure 1) next to Leishmania NT4 469 
sequences, and its predicted structural similarity with those carriers (Figure S1), indicate that 470 
TcrNB2 could be a low-affinity purine nucleobase transporter [43]. This ORF was amplified 471 
from genomic DNA of T. cruzi Y strain, cloned into pHD1336 vector and transfected into 472 
procyclic forms of TbNBT-KO. Two clones of TbNBT-KO+TcrNB2 were randomly selected 473 
for the transport assays in parallel with TbNBT-KO+EV. A large number of radiolabelled 474 
natural purines and pyrimidines (adenine, adenosine, guanine, guanosine, hypoxanthine, 475 
inosine, cytidine, thymine, thymidine, uracil, uridine) and the hypoxanthine analogue 476 
allopurinol were screened at 50 nM, in transporter assay buffers with pH 7.3 and 6.0, but no 477 
difference in transport rates in TbNBT-KO+TcrNB2 clones and TbNBT-KO+EV was observed 478 
in either condition (data not shown). The pH 6.0 conditions were tested because of the 479 
phylogenetic proximity to the acid-activated Leishmania NT4 transporters. It should be noted, 480 
however, that the procyclic forms of TbNBT-KO showed a very high level of [3H]-Adenine 481 
uptake, which might have masked any adenine transport capacity associated with the 482 
expression of TcrNB2 in these cells. This adenine transporter in PCF was found to have a Km 483 
of 359 ± 37 nM and Vmax of 0.64 ± 0.1 pmol.(10
7 cells)-1.s-1 when cells were incubated with 50 484 
nM of [3H]-Adenine in presence of increasing concentrations of unlabelled adenine. This Km is 485 
very close to that recently reported by us for ADET1 in T. brucei bloodstream forms [17], and 486 
likely represents the same transporter. Similarly, transport rates of the purine nucleosides 487 
adenosine, inosine and guanosine were high in the TbNBT-KO+EV cells, as a result of the 488 
expression of P1-type transporters. 489 
 We therefore attempted to express TcrNB2 in another trypanosomatid system. To do 490 
so, TcrNB2 was cloned into a pNUS vector [52] and transfected into L. mexicana 491 
promastigotes. After selection with G418, the populations transfected with empty pNUS or 492 
with pNUS containing TcrNB2 were used in uptake assays. Again, no significant difference 493 
was found between the cell lines, using 50 nM each of tritiated adenine, adenosine, guanine, 494 
hypoxanthine, inosine, uracil, and uridine, over 1 min intervals (data not shown). 495 
 496 
3.3. Transcriptional level of ENTs throughout T. cruzi life cycle 497 
 The expression level of each of the ENT genes was assessed using qRT-PCR with 498 
mRNA isolated from each of the main lifecycle stages of T. cruzi, and normalised to the 499 
expression level of GAPDH. Each of the genes was highly expressed in at least one lifecycle 500 
stage, and the expression levels of all of the genes appear to be highly regulated, indicating 501 
important functions (Figure 9). The amastigote stage, which has a high rate of replication, 502 
expressed all four ENTs robustly, consistent with a high demand for high-affinity salvage of 503 
both purines and pyrimidines. In contrast, both metacyclic and bloodstream trypomastigotes, 504 
which do not have a high rate of nucleic acid synthesis or cell division, displayed a low level 505 
of ENT transporter expression. Epimastigotes displayed a robust expression of TcrNT2 but at 506 
most modest levels for the other three transporters, probably due to the high availability of 507 
purines in LIT medium. 508 
 509 
3.4. TcrNT2 is a potential drug carrier 510 
 Given the apparent requirement of T. cruzi amastigotes for external pyrimidines [53] 511 
and the existence and current medicinal use of pyrimidine analogues for the treatment of cancer 512 
and viral infections [54–57], as well as the high affinity of TcrNT2 for 2’-deoxyuridine, we 513 
evaluated the potential of TcrNT2 to act as a carrier for the anticancer drug 5-Fluoro-2’-514 
deoxyuridine (5F-2’dUrd) and found that TbNBT-KO cells became almost 40-fold more 515 
sensitive to 5F-2’dUrd upon expression of TcrNT2 (Figure 10). The cell lines s427WT, 516 
TbNBT-KO and TbNBT-KO+EV were all equally sensitive to 5F-2’dUrd (P>0.6 by Unpaired 517 
Student’s T-test), with an average EC50 of 17.7 ± 1.85 μM. In contrast, TbNBT-KO+TcrNT2 518 
displayed an EC50 of 0.47 ± 0.045 μM for 5F-2’dUrd (P<0.005 by Unpaired Student’s T-test 519 
to all three control cell lines; Figure 10 A). The EC50 for the control drug, pentamidine, whose 520 
internalisation in procyclics is independent of ENTs [58,59] but is instead mediated almost 521 
exclusively by aquaglyceroporin 2 [60–62], did not significantly differ between all the cell 522 
lines generated in comparison to s427WT parasites (P>0.2 by Unpaired Student’s T-test; 523 
Figure 10 B). These results clearly show that the change in the EC50 for 5F-2’dUrd in TbNBT-524 
KO+TcrNT2 is due to the expression of this transporter. We, therefore, can propose TcrNT2 525 
as a potential drug carrier in T. cruzi. 526 
 527 
4. Discussion 528 
 Among the nutrients T. cruzi needs, purines are and pyrimidines seem to be essential 529 
for the growth of the parasite [13,53]. To date, only ENT genes have been identified as 530 
encoding nucleoside and nucleobase transporters in protozoa [13], although the presence of 531 
non-ENT nucleobase transporters has been suggested, owing to the observation of highly 532 
specific uptake activities for uracil, adenine and hypoxanthine in T. brucei brucei and L. major 533 
that could not be linked to any of the ENT genes in their genomes [15–17]. However, almost 534 
the entirety of nucleoside transport studies in trypanosomatids have been performed with T. 535 
brucei brucei and Leishmania spp., although nucleoside salvage is essential for T. cruzi and 536 
might be quite different from the other kinetoplastid species, owing to its localisation in the 537 
host cell cytosol.  We therefore decided to systematically characterise the ENT genes from T. 538 
cruzi, by expressing each in a genetically adapted procyclic T. brucei cell line, TbNBT-KO, 539 
that expresses only P1-type purine nucleoside transporters. This cell line displayed an 86% 540 
reduced hypoxanthine uptake rate, confirming the hypothesis of by Burchmore et al. (2003) 541 
that the NT8 genes are responsible for almost all of the hypoxanthine transport in procyclics 542 
[27]. In contrast, the deletion of the NT8 cluster in T. brucei bloodstream forms, as well as AT-543 
A/NT11 and AT-E/NT12 had only a minor effect on nucleobase transport [17]. 544 
 The comparison of T. cruzi ENT genomic sequences with sequences from other 545 
trypanosomatids (T. brucei, T. congolense and Leishmania spp.), most of which have been 546 
previously characterised [23,27,28,38,39,43,49,63–68], revealed the presence of four full-547 
length ENT-family genes in T. cruzi. Phylogenetic analysis suggested that TcrNB1 could 548 
encode for a high-affinity nucleobase transporter, which was confirmed by its biochemical 549 
characterisation upon expression in TbNBT-KO, yielding a Km of 93.8 ± 4.7 nM for 550 
hypoxanthine, which is very close to that measured for H2 in T. brucei bloodstream forms [19]. 551 
Like H2, TcrNB1 showed much higher affinity for hypoxanthine and guanine than for others 552 
purine, and their Ki values for adenine were virtually identical. In addition, the much lower 553 
affinity of TcrNBT1 for purine nucleosides compared to nucleobases also resembles H2: the 554 
Ki of both transporters for guanosine was very similar, and both showed lower affinity for 555 
inosine compared to guanosine, although their respective nucleobases (hypoxanthine and 556 
guanine) had very similar affinities in both H2 and TcrNB1. The only minor differences rely 557 
on the affinity for adenosine, which did not affect the transport of [3H]-Hypoxanthine by 558 
TcrNB1 at 1 mM, while its Ki for H2 was determined to be 590 ± 175 μM [19], and on their 559 
affinity for pyrimidines: H2 presented measurable Ki values for thymine and uracil (82 ± 25 560 
μM and 60 ± 14 μM, respectively), while TcrNB1 was not affected by these nucleobases, but 561 
was somewhat more sensitive to inhibition by 1 mM of pyrimidine nucleosides (cytidine, 562 
thymidine and uridine). 563 
 The phylogenetic tree also placed TcrNT1 close to the T. brucei P1 and P2 sequences 564 
and to the T. congolense P1-type transporter TcoAT1, and, somewhat more distantly, to 565 
Leishmania NT2 transporters, which indicated that TcrNT1 might be a high-affinity nucleoside 566 
transporter [20,23,48,64].  Consistent with this analysis, the expression in TbNBT-KO showed 567 
that TcrNT1 has very high-affinity for inosine and guanosine, with much lower affinity for 568 
adenosine and purine nucleobases. This selectivity pattern closely matches that of the 569 
Leishmania NT2 transporters [39,64], with the main difference being that L. donovani NT2 570 
(LdNT2) has 6-fold higher affinity for inosine than for guanosine [64], while both substrates 571 
are virtually equally recognized by TcrNT1. Moreover, TcrNT1 differs from LdNT2 in its 572 
affinity for adenosine and hypoxanthine, as we determined Ki values for them around the mid-573 
micromolar range for TcrNT1, whereas Carter et al. (2000) reported that 100 μM of these 574 
purines failed to inhibit the transport of 1 μM of [3H]-Inosine by L. donovani promastigotes. 575 
The moderate affinity for adenosine also differentiates TcrNT1 from T. brucei P1 and P2, 576 
which recognise adenosine in the submicromolar range [20,48]. 577 
 We further characterised the transport activity mediated by TcrNT2, which grouped 578 
next to the Leishmania NT1 adenosine/pyrimidine nucleoside transporter sequences, forming 579 
a group outside the main tree of kinetoplastid ENT genes. Its expression in TbNBT-KO 580 
procyclics showed that like the Leishmania NT1 genes, TcrNT2 transports pyrimidine 581 
nucleosides, but, in contrast to NT1 of L. donovani [37,38], L. major or L. mexicana [39], it 582 
had no affinity for adenosine at physiological levels. In addition, TcrNT2 showed a very clear 583 
preference for 2’-deoxypyrimidines over the analogous ribonucleosides, which was not 584 
observed for LdNT1 or any other known ENT transporter. TcrNT2 thus constitutes the first 585 
identification of a protozoan gene coding for a pyrimidine-specific transporter. 586 
 Given the preference of TcrNT2 for pyrimidine nucleosides, its low affinity for uridine 587 
is quite unexpected as uridine monophosphate is the end product of pyrimidine de novo 588 
biosynthesis, and the key nucleotide in pyrimidine salvage and interconversion, and could be 589 
formed from uridine by action of uridine phosphorylase and uracil phosphoribosyltransferase, 590 
as in Leishmania [39] and in T. brucei [40,69]. Thymidine, the main substrate for TcrNT2, on 591 
the other hand, could only be converted to thymine or to TMP [40,70], but the recent finding 592 
of sequences encoding thymine 7-hydroxylase-like proteins in T. brucei [71] opens the 593 
possibility that trypanosomes might use thymidine and/or thymine as pyrimidine source, due 594 
to the possibility of converting these nutrients back to uracil by the action of thymine 7-595 
hydroxylase and uracil 5-carboxylic acid decarboxylase [71,72]. However, it must be 596 
remembered that T. brucei bloodstream forms do not salvage any pyrimidine nucleosides at 597 
physiological concentrations, that their biosynthesis pathway is sufficient for their needs, and 598 
although they express a high affinity uracil transporter [40], this carrier is not essential [73]. 599 
The possibility of a uracil transporter in T. cruzi is yet to be investigated although the genes 600 
encoding the T. brucei and Leishmania uracil transporters have not yet been identified [15]. 601 
 Another possibility that could be argued is that T. cruzi might have a deficiency in the 602 
conversion of dUMP to TMP by thymidylate synthase and, therefore, circumvents this by 603 
scavenging thymidine from the host followed by its phosphorylation via thymidine kinase. This 604 
seems to be unlikely as the T. cruzi DHFR-TS (dihydrofolate reductase-thymidylate synthase) 605 
has been cloned, heterologously expressed in Escherichia coli and shown to have an active 606 
thymidylate synthase activity (Km of 1.02 ± 0.05 μM for dUMP)  [74]. Moreover, Brandan et 607 
al. (2011) were not able to delete both alleles of DHFR-TS from T. cruzi Tulahuen and TCC 608 
strains, indicating the essentiality of this gene to the parasite — a conclusion that is further 609 
strengthened by the decreased infectivity of DHFR-TS single knockout parasites in mice [75]. 610 
We also attempted to characterize the activity of TcrNB2 by expression in TbNBT-KO 611 
procyclic forms and in L. mexicana promastigotes but were unable to identify a substrate. 612 
However, we conducted the screening for substrate with radiolabel concentrations of 0.05 µM, 613 
which is self-selecting for a high affinity carrier, as almost all kinetoplastid nucleoside and 614 
nucleobase transporters are. Therefore, it is possible that TcrNB2 is a very low affinity 615 
transporter, resembling LmjNT4. The fact that LmjNT4 is an adenine transporter, and that none 616 
of the other T. cruzi ENT genes encode for an aminopurine transporter, leads us to direct 617 
follow-on research efforts in that direction. Alternative explanations for our inability to identify 618 
a substrate for TcrNB2 might be that it could be an intracellular transporter, or that its 619 
expression in our experimental cell lines was low. However, it seems to be robustly expressed 620 
in T. cruzi amastigotes and it is therefore highly likely to play a role in purine salvage in this 621 
parasite. 622 
The expression of TcrNB1 in the amastigote stage, which is corroborated by its high 623 
level of transcription as verified by qRT-PCR, could explain the reduction in the intracellular 624 
concentration of hypoxanthine and adenine in infected cardiomyocytes [26]. However, this 625 
being an oxopurine nucleobase transporter, it alone does not explain the much higher reduction 626 
in adenine than in hypoxanthine intracellular concentrations [26], leading to the conclusion that 627 
either T. cruzi must express an as yet unidentified adenine transporter, possibly TcrNB2, which 628 
is also highly transcribed in the amastigote stage, and/or a transporter orthologous to T. brucei 629 
ADET1 [17], or an ecto-adenine deaminase activity.  630 
Similarly, the presence of a high-affinity inosine/guanosine transporter in amastigotes 631 
might explain the reduction in the intracellular concentration of both nucleosides in T. cruzi-632 
acutely infected cardiomyocytes [26]. Consistent with the presence of such transporting 633 
mechanism is the transcription and expression of a nucleoside triphosphate 634 
diphosphohydrolase (NTPDase) by T. cruzi [76–78], which presented higher capacity to 635 
convert guanine nucleotides (GDP and GTP) than adenine nucleotides (ADP and ATP) [76,77]. 636 
Although this NTPDase activity would lead to the formation of monophosphate nucleotides, it 637 
could be coupled with ecto-5’nucleotidases to form free nucleosides [79]. In addition, the 638 
NTPDase is expressed in all the three main biological forms of the parasite, epimastigote, 639 
trypomastigote and amastigote [76], although its transcription and activity are higher in the 640 
infective trypomastigote and amastigote forms [78], and is distributed all over the surface of 641 
the parasite, which points to its participation in the acquisition of these essential nutrients by 642 
T. cruzi [77]. 643 
 Finally, given the presence of a high-affinity pyrimidine nucleoside transporter in T. 644 
cruzi, the apparent need of pyrimidine uptake by amastigotes [53], the historical use of 645 
pyrimidine-analogues for treatment of cancer and viral infections [54–57], and the limited and 646 
cumbersome chemotherapeutical arsenal against Chagas’ disease  (restricted to two drugs, 647 
Benznidazole and Nifurtimox, neither of them approved by the FDA [7]), we tested the 648 
possibility of using the anti-cancer drug 5F-2’dUrd against T. cruzi. The expression of TcrNT2 649 
in TbNBT-KO greatly sensitized the cells to this pyrimidine analogue, showing it to be a good 650 
substrate. This demonstrates the potential use of currently approved and clinically used 651 
anticancer and antiviral thymidine or deoxyuridine analogues against T. cruzi. 652 
 In summary, we established T. brucei NBT-KO cells as surrogate system for the 653 
systematic expression and characterisation of purine and pyrimidine transporters from other 654 
trypanosomatids and used it to characterize three of the four ENT genes from T. cruzi Y strain, 655 
which revealed the existence of very high-affinity purine and pyrimidine transporters in this 656 
parasite, including the first pyrimidine-specific protozoan transporter and high affinity carriers 657 
for oxopurine nucleosides and nucleobases. We propose that these transporters could also be 658 
exploited as drug carriers for the treatment of Chagas’ disease. 659 
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 Figure 1. Phylogenetic tree showing the relationship between Equilibrative Nucleoside 966 
Transporter genes from trypanosomatids. A clear separation between nucleobase (top 967 
branch) and nucleoside (bottom branch) transporters can be observed. Sequences were 968 
obtained from TriTrypDB, aligned with Clustal Omega and subjected to a Maximum 969 
Likelihood analysis with 1000 bootstraps using MEGA 6.0.  The Toxoplasma gondii 970 
TGVEG 233130 nucleoside transporter was used as external group. 971 
 972 
Figure 2. Uptake of 100 nM [3H]-Hypoxanthine is greatly reduced in T. brucei procyclic forms 973 
upon knockout of the NT8 cluster. Wildtype s427 parasites transported [3H]-974 
Hypoxanthine at 0.036 ± 0.007 pmol.(107 cells)-1.s-1 (filled circles), whereas TbNBT-975 
KO cells showed a rate of uptake of 0.005 ± 0.0005 pmol.(107 cells)-1.s-1 (filled 976 
diamonds). In both cases slope was consistently different from zero (P<0.005, F-test). 977 
The addition of 1 mM unlabelled hypoxanthine (open symbols) completely saturated the 978 
transporters, and made the slopes not different from zero (P>0.2; F-test). 979 
 980 
Figure 3. Expression of TcrNB1 in TbNBT-KO cells dramatically increased the rate of 981 
transport of 50 nM [3H]-Hypoxanthine in comparison to cells transfected with an empty 982 
vector (TbNBT-KO+EV), in a linear phase of six seconds (blue line; r2 = 0.99). The 983 
addition of 1 mM unlabelled hypoxanthine completely saturated the transport. Whereas 984 
the slope of the TcrNB1 regression was significantly non-zero (P<0.0001, F-test), the 985 
slope of the TbNBT-KO+EV-mediated transport was not significantly different from 986 
zero (P=0.15). 987 
 988 
Figure 4. TcrNB1 is a high-affinity purine nucleobase transporter. A. Incubation of TbNBT-989 
KO + TcrNB1 cells with 50 nM of [3H]-Hypoxanthine in presence of increasing 990 
concentrations of unlabelled hypoxanthine gave an inhibition curve with Hillslope near 991 
-1 (inset), whose conversion into a Michaelis-Menten plot yielded a Km of 93.8 ± 4.7 992 
nM.  When TbNBT-KO + TcrNB1 was exposed to 50 nM of [3H]-Hypoxanthine in 993 
presence of increasing concentrations of other nucleobases (B), we verified it shows 994 
very high-affinity for guanine (Ki of 121.9 ± 21.4 nM; triangles), good affinity for 995 
adenine (Ki of 3.73 ± 0.5 μM; circles) and low affinity for xanthine (Ki of 18.36 ± 1.83 996 
μM; squares). C. Pyrimidine nucleobases and nucleosides at 1 mM competed with 50 997 
nM of [3H]-Hypoxanthine for transport via TcrNB1, which was mostly affected by 998 
thymidine, uridine and cytidine. *P<0.05, **P<0.01 by Unpaired T-test. Figures A and B 999 
show one representative out of three independent experiments in triplicate. C shows 1000 
average ± SEM of three independent experiments in triplicate. 1001 
 1002 
Figure 5. A. Inhibitory effect of 2’F-Ado on the uptake of [3H]-Inosine by TbNBT-KO+EV 1003 
and TbNBT-KO+TcrNT1. Transport of 50 nM of [3H]-Inosine over an interval of 8 s 1004 
was measured in the presence of increasing concentrations of 2’-F-adenosine. This was 1005 
monophasic in the control cells (TbNBT-KO; red circles), reflecting inhibition of the P1 1006 
transporter only, with high affinity. The dotted line divides the biphasic inhibition profile 1007 
by 2’F-Ado (blue squares) of, firstly, the P1 transporter in the TcrNT1-expressing cells 1008 
(above the line, high affinity phase), and the low affinity inhibition of TcrNT1 in 1009 
TbNBT-KO + TcNT1 (below the line, low affinity phase). B. Uptake of [3H]-Inosine as 1010 
a function of time by TbNBT-KO + EV and TbNBT-KO + TcrNT1. Cells were 1011 
incubated with 50 nM of [3H]-Inosine in absence and presence of inhibitors (3.3 μM of 1012 
2’-F-Adenosine or 1 mM of inosine) and the reaction was stopped at the referred time, 1013 
showing a linear phase of transport of 12 s (r2=0.99) . A and B show a representative out 1014 
of at least three independent experiments in triplicate. 1015 
 1016 
Figure 6. TcrNT1 is high-affinity inosine/guanosine transporter. A. TbNBT-KO cells 1017 
expressing TcrNT1 were incubated with 50 nM of [3H]-Inosine for 8 s in the presence 1018 
of increasing concentrations of unlabelled inosine and a dose-dependent inhibition curve 1019 
with Hillslope near -1 (inset) was observed. Conversion of the data into a Michaelis-1020 
Menten plot yielded a Km of 1.0 ± 0.04 μM for inosine (n=4). Incubation of TbNBT-KO 1021 
+ TcrNT1 cells with 50 nM of [3H]-Inosine in presence of increasing concentrations of 1022 
adenosine (down triangles), guanosine (up triangles), hypoxanthine (circles) and 1023 
xanthine (squares) (B) showed TcrNT1 has higher affinity for oxopurine nucleosides. C. 1024 
Incubation of TbNBT-KO + TcrNT1 cells with 50 nM of [3H]-Inosine in presence of 1025 
adenine or pyrimidine nucleobases and nucleosides at 1 mM showed that TcrNT1 has 1026 
no physiologically relevant affinity for these molecules. *P<0.05 by Unpaired Student’s 1027 
T-test. A and B show a representative out of at least three independent experiments. C 1028 
shows average ± SEM of three independent assays. All assays were carried out in 1029 
presence of 3.3 μM of 2’F-Ado in the assay buffer. 1030 
 1031 
Figure 7. Uptake of [3H]-Thymidine as a function of time in TbNBT-KO + EV and TbNBT-1032 
KO + TcrNT2 cells. Cells were incubated with 25 nM of [3H]-Thymidine and the 1033 
reaction was stopped at different times with ice-cold unlabelled thymidine in assay 1034 
buffer (1 mM). Transport was linear for at least sixty seconds (r2=0.99; blue line) in 1035 
TbNBT-KO + TcrNT2, which was completely saturated by addition of 1 mM of 1036 
unlabelled thymidine (open symbols). Figure shows a representative experiment in 1037 
triplicate. 1038 
 1039 
Figure 8. TcrNT2 is a high-affinity thymidine transporter. A. TbNBT-KO + TcrNT2 cells were 1040 
incubated with 25 nM of [3H]-Thymidine in the presence of increasing concentrations 1041 
of unlabelled thymidine for 30 s and a dose-dependent inhibition curve with Hillslope 1042 
near -1 (inset) was observed. Conversion of the data into a Michaelis-Menten plot 1043 
yielded a Km of 223.5 ± 7.1 nM (n=3). The incubation of TbNBT-KO + TcrNT2 cells 1044 
with 25 nM of [3H]-Thymidine in the presence of increasing concentrations of other 1045 
pyrimidine nucleosides (B) revealed the preference of TcrNT2 for 2’-deoxypyrimidines, 1046 
as the affinity for 2’-deoxyuridine (Ki = 1.11 ± 0.1 μM; up triangles) was 59-fold higher 1047 
than for uridine (Ki = 65.5 ± 6.0 μM; circles). Cytidine showed very low affinity for 1048 
TcrNT2, yielding a Ki of 728 ± 71 μM. A and B show one representative out of three 1049 
independent experiments in triplicate. 1050 
 1051 
Figure 9. qRT-PCR of mRNA isolated from T. cruzi epimastigotes (EPI), metacyclic 1052 
trypomastigotes (META), amastigotes (AMA) and bloodstream trypomastigotes 1053 
(TRYP) for each of the T. cruzi ENT genes. Bars represent the average ± SEM of 3 1054 
independent biological replicates, each performed in triplicate. Each biological replicate 1055 
was normalised to the expression level of the GAPDH gene in each of the lifecycle 1056 
stages. N.D., not detectable. 1057 
 1058 
Figure 10. Sensitivity of procyclic T. brucei nucleobase transporter-knockout cell lines to 1059 
drugs. Alamar blue assays revealed that the heterologous expression of TcrNT2 by 1060 
TbNBT-KO sensitised the cells to 5-Fluoro-2’-deoxyuridine by 38-fold (A), while the 1061 
EC50 for Pentamidine (B) remained unchanged. 
***P<0.005 by Unpaired Student’s T-1062 
test. Bars represent average ± SEM of three independent experiments. 1063 
